Recro Pharma found using ticker (REPH) now have 2 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The range between the high target price and low target price is between 10 and 5 calculating the average target price we see 7.5. Given that the stocks previous close was at 2.97 this would indicate that there is a potential upside of 152.5%. The 50 day MA is 2.28 and the 200 moving average now moves to 3.02. The company has a market cap of $78m. Find out more information at: http://www.recropharma.com
Recro Pharma a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I and changed its name to Recro Pharma in August 2008. Recro Pharma was founded in 2007 and is based in Malvern, Pennsylvania.